ClinicalTrials.gg
CompletedNCT01724359PERFLEXUpdated Mar 15, 2013Results posted

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia

A Phase 4 interventional study of Paliperidone ER in Schizophrenia, sponsored by Janssen-Cilag, S.A.. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-15.

Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
74th of 115
95 · median 178
Started
2008
with 12 others
Phase 4
42 of 115
5 open now
Registered
84th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 74th largest by enrollment, is one of 13 that started in 2008, is one of 42 in phase 4, and was the 84th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy, safety and tolerability of flexible, once-daily doses of paliperidone extended-release (ER) in patients with schizophrenia from Argentina and Colombia that previously failed treatment with other antipsychotic agents.

Read the detailed description

This is a single arm (one group of patients), open-label (all people know the identity of the intervention) multicenter 6-month study. Throughout the study flexible dosing of paliperidone ER in a range of 3 to 12 mg/day may be used. Flexible dosing will allow investigators to adjust the dosage of each patient based on the individual needs. Patients will receive 3, 6, 9 or 12 mg of paliperidone ER once daily for 6 months. The tablets will be taken orally. Adjustment of the dosage will be done at the investigator's discretion, based on the individual patient's clinical response and tolerability to the study drug.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone extended-release (ER)
  • Antipsychotic agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient meets the criteria for schizophrenia
  • Patient is previously non-acute and has been given an adequate dose of an appropriate oral antipsychotic for an adequate period of time prior to enrollment, but previous treatment is considered unsuccessful due to one or more of the following reasons: lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons to switch to another antipsychotic medication
  • Patient is healthy on the basis of a physical examination and vital signs at screening
  • Women must be for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of before entry and throughout the study

Exclusion criteria

Exclusion Criteria:

  • Patients on clozapine, any conventional depot neuroleptic or risperidone long-acting injections during the last 3 months
  • Patients with serious unstable medical condition, including known laboratory abnormalities
  • Patients with history or current symptoms of tardive dyskinesia and neuroleptic malignant syndrome
  • Patients judged to be at high risk for adverse events, violence, or self-harm
  • Patients with known to paliperidone ER or to risperidone
  • Patients with a current use or known history (over the past 6 months) of substance dependence
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Paliperidone ER

    Drug: Paliperidone ER

Interventions

  • The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score

    The PANSS Positive Subscale assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

    Time frame: Baseline, Week 26

  2. Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score

    The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

    Time frame: Baseline, Week 26

  3. Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - General Psychopathology Subscale Score

    The PANSS General Psychopathology Subscale Score assesses 16 general psychopathology symptoms. The symptoms are rated on a 7-point scale, with a range of 16 (absent) to 112 (extreme psychopathology).

    Time frame: Baseline, Week 26

  4. Clinical Global Impression-Severity (CGIS)

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients". Higher scores indicate worsening.

    Time frame: Baseline, Week 26

  5. Personal and Social Performance (PSP) Scale

    This PSP assesses the degree of a patient's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patients with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\< 30, functioning so poorly as to require intensive supervision.

    Time frame: Baseline, Week 26

  6. Health Status as Measured by Self-rated Health Status Survey SF-36

    The SF-36 is designed to examine a person's perceived health status. The SF-36 includes one multi-item scale measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health. Answers to each question are scored and summed to produce raw scale scores for each health concept which are then transformed to a 0 - 100 scale, a high score defining a more favorable health state. An aggregate summary measure is calculated by averaging the scores from the eight health concepts.

    Time frame: Baseline, Week 26

  7. Sleep Evaluation Scale

    This self-administered scale rates the quality of sleep. Patients will indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well).

    Time frame: Baseline, Week 26

  8. Daytime Drowsiness Evaluation Scale

    This self-administered scale rates the daytime drowsiness. Patients will indicate on an 11-point scale how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time).

    Time frame: Baseline, Week 26

07

Results

Posted Mar 15, 2013

Participant flow

Participant flow — Overall Study
MilestonePaliperidone Extended-release (ER)
Started95
Completed64
Not completed31
Withdrew: Adverse event10
Withdrew: Death1
Withdrew: Other20

Outcome measures

PrimaryChange From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 70)83.99 ± 22.16
Week 26 (n= 70)53.70 ± 18.82
SecondaryChange From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score

The PANSS Positive Subscale assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 70)18.53 ± 7.30
Week 26 (n= 70)11.16 ± 4.95
SecondaryChange From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score

The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 70)23.69 ± 6.42
Week 26 (n= 70)14.64 ± 5.24
SecondaryChange From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - General Psychopathology Subscale Score

The PANSS General Psychopathology Subscale Score assesses 16 general psychopathology symptoms. The symptoms are rated on a 7-point scale, with a range of 16 (absent) to 112 (extreme psychopathology).

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) - General Psychopathology Subscale Score
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 70)41.77 ± 11.39
Week 26 (n= 70)27.90 ± 10.34
SecondaryClinical Global Impression-Severity (CGIS)

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients". Higher scores indicate worsening.

Time frame:
Baseline, Week 26
Reported as:
Number · participants
Clinical Global Impression-Severity (CGIS)
participantsPatients at Baseline: Paliperidone Extended-release (ER)Patients at Week 26: Paliperidone Extended-release (ER)
Normal, not at all ill29
Borderline mentally ill321
Mildly ill1426
Moderately ill3920
Markedly ill265
Severely ill102
Among the most extremely ill10
SecondaryPersonal and Social Performance (PSP) Scale

This PSP assesses the degree of a patient's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patients with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\< 30, functioning so poorly as to require intensive supervision.

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Personal and Social Performance (PSP) Scale
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 95)52.06 ± 15.27
Week 26 (n= 78)68.24 ± 15.91
SecondaryHealth Status as Measured by Self-rated Health Status Survey SF-36

The SF-36 is designed to examine a person's perceived health status. The SF-36 includes one multi-item scale measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health. Answers to each question are scored and summed to produce raw scale scores for each health concept which are then transformed to a 0 - 100 scale, a high score defining a more favorable health state. An aggregate summary measure is calculated by averaging the scores from the eight health concepts.

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Health Status as Measured by Self-rated Health Status Survey SF-36
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 95)56.39 ± 18.14
Week 26 (n= 86)67.02 ± 21.56
SecondarySleep Evaluation Scale

This self-administered scale rates the quality of sleep. Patients will indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well).

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Sleep Evaluation Scale
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 71)6.80 ± 2.69
Week 26 (n= 71)7.66 ± 2.52
SecondaryDaytime Drowsiness Evaluation Scale

This self-administered scale rates the daytime drowsiness. Patients will indicate on an 11-point scale how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time).

Time frame:
Baseline, Week 26
Reported as:
Mean · scores on a scale
Daytime Drowsiness Evaluation Scale
scores on a scalePaliperidone Extended-release (ER)
Baseline (n= 71)4.68 ± 3.21
Week 26 (n= 71)2.58 ± 2.93

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Extended-release (ER)—7/95 (7.4%)39/95 (41.1%)
Most frequent serious events
Most frequent serious events
EventPaliperidone Extended-release (ER)
Psychotic episodePsychiatric disorders3/95
Clinical deteriorationGeneral disorders1/95
AppendicitisGastrointestinal disorders1/95
Major depressive disorderPsychiatric disorders1/95
Worsening of the psychiatric condition with aggressive behaviorPsychiatric disorders1/95
Most frequent other events
Most frequent other events
EventPaliperidone Extended-release (ER)
InsomniaPsychiatric disorders24/95
AkathisiaNervous system disorders22/95
ParkinsonismNervous system disorders15/95

Baseline characteristics

Age Continuous
Age Continuous(years)Paliperidone Extended-release (ER)
Mean35.86 ± 12.28
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone Extended-release (ER)
Female41
Male54
Region of Enrollment
Region of Enrollment(participants)Paliperidone Extended-release (ER)
Argentina37
Colombia58
08

Study locations

6 sites
  • Buenos Aires N/A, Argentina
  • Buenos Aires, Argentina
  • Rosario, Argentina
  • Bogota, Colombia
  • Cali, Colombia
  • Medellin, Colombia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2012
First posted
Nov 9, 2012
Start
Feb 2008
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Mar 15, 2013
Last update
Mar 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01724359
Responsible party
Sponsor
First posted
Nov 9, 2012
Start date
Feb 2008
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Mar 15, 2013
Last update
Mar 15, 2013

Study contacts

Janssen-Cilag S.A. Clinical Trial
study director · Janssen-Cilag, S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion